Start the conversation
Biotechnology is a big opportunity. And China is a big market.
Combine the two and you have a biotech market – and big potential for investment profits.
Today I'm talking with Money Map Press Executive Editor William Patalon III about a big profit play in the Chinese biotech market.
It's a brand-new recommendation…
The Best Chinese Biotech Play
Bill Patalon: Michael, you and I both like the long-term potential of the "right" China-focused investments. And we're both big believers in the long-term upside for the biotech sector. You've told me about a stock that offers a "double-barreled" return by focusing on both of these opportunity/catalyst areas – China Biologic Products Inc. (Nasdaq: CBPO).
Let's start by telling folks what is it about biotech, and about China, that you like?
Michael Robinson: Well, Bill, I know that you – like me – have been following biotech for a long time. In fact, I believe you had the biotech beat at The Baltimore Sun.
BP: (laughing) You have a good memory, Michael.
MR: Well, I've been following biotech since the early 1980s, and I can tell you this emphatically: We've now reached the point where many of the innovations and breakthroughs that were on the drawing boards for years are finally coming to fruition.
That's why you see both small-cap and mega-cap biotech and Big Pharma companies coming out with so many new products over the past five years. And it's why there are hundreds more in their pipelines.
More to the point, the United States has an aging population, meaning folks need those drugs to improve their health and extend their lifespans, which continue to rise.
BP: Then there's China.
MR: That's right, Bill. Then there's China.
In China, we have a massive population of 1.3 billion people.
I mean, think about that.
BP: That's more than four times the 2014 U.S. population of 318.9 million. And for some additional context, China's middle class is bigger than the entire U.S. population.
MR: That's right, Bill.
BP: In fact, by 2022, according to McKinsey Greater China, that Asian giant could have a middle class of 630 million people. And it's all because of economic growth. That would represent 78% of all urban households, up from 68% in 2012 and 4% in 2000.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.